Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Current Liabilities (2023 - 2025)

CG Oncology's Total Current Liabilities history spans 3 years, with the latest figure at $30.8 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 44.31% year-over-year to $30.8 million; the TTM value through Dec 2025 reached $30.8 million, up 44.31%, while the annual FY2025 figure was $30.8 million, 44.31% up from the prior year.
  • Total Current Liabilities reached $30.8 million in Q4 2025 per CGON's latest filing, up from $30.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $30.8 million in Q4 2025 to a low of $10.0 million in Q1 2024.
  • Average Total Current Liabilities over 3 years is $20.8 million, with a median of $21.4 million recorded in 2024.
  • The largest YoY upside for Total Current Liabilities was 156.31% in 2025 against a maximum downside of 44.31% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $14.3 million in 2023, then surged by 49.91% to $21.4 million in 2024, then skyrocketed by 44.31% to $30.8 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Total Current Liabilities are $30.8 million (Q4 2025), $30.5 million (Q3 2025), and $30.4 million (Q2 2025).